title: Expanding the diversity of allosteric bcr-abl inhibitors.
abstract: Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competitive inhibitors of cellular Bcr-Abl kinase activity that target the myristate binding site. Here, we used cell-based structure-activity relationships to guide the optimization and diversification of ligands that are capable of binding to the myristate binding site and rationalize the findings based upon an Abl-compound 1 cocrystal. We elucidate the structure-activity relationships required to obtain potent antiproliferative activity against Bcr-Abl transformed cells and report the discovery of new compounds (5g, 5h, 6a, 14d, and 21j-I) that display improved potency or pharmacological properties. This work demonstrates that a variety of structures can effectively target the Bcr-Abl myristate binding site and provides new leads for developing drugs that can target this binding site.
authors.affiliation: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: Xianming
authors.initials: X
authors.lastname: Deng
authors.forename: Barun
authors.initials: B
authors.lastname: Okram
authors.forename: Qiang
authors.initials: Q
authors.lastname: Ding
authors.forename: Jianming
authors.initials: J
authors.lastname: Zhang
authors.forename: Yongmun
authors.initials: Y
authors.lastname: Choi
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Adrián
authors.forename: Amy
authors.initials: A
authors.lastname: Wojciechowski
authors.forename: Guobao
authors.initials: G
authors.lastname: Zhang
authors.forename: Jianwei
authors.initials: J
authors.lastname: Che
authors.forename: Badry
authors.initials: B
authors.lastname: Bursulaya
authors.forename: Sandra W
authors.initials: SW
authors.lastname: Cowan-Jacob
authors.forename: Gabriele
authors.initials: G
authors.lastname: Rummel
authors.forename: Taebo
authors.initials: T
authors.lastname: Sim
authors.forename: Nathanael S
authors.initials: NS
authors.lastname: Gray
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001665:Binding Sites; D002461:Cell Line, Transformed; D000069439:Dasatinib; D004357:Drug Synergism; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics; D051379:Mice; D008958:Models, Molecular; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib